GlassScriptPhysician profile
Brittani Reed
NPI 1316596075
$5,680.50
in general payments reported to CMS, 2019-2025
54 companies · $1,589 in 2025
The $1,589 reported for 2025 was more than what 91% of Nurse Practitioner providers received nationally (typical 2025 total: $174).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2021: $843 · 2022: $514 · 2023: $1,073 · 2024: $1,661 · 2025: $1,589.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $3,712 · Education: $612.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $3,711.65 |
| Education | $611.53 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Lilly USA, LLC | $697.50 | 2021-2024 | Jaypirca, Verzenio, Retevmo |
| Novartis Pharmaceuticals Corporation | $461.97 | 2021-2025 | |
| Pfizer INC. | $399.01 | 2022-2025 | |
| Janssen Biotech, INC. | $320.73 | 2021-2025 | Rybrevant, Darzalex, Talvey |
| Genentech USA, INC. | $287.57 | 2022-2025 | Polivy, Tecentriq, Lunsumio |
| Abiomed | $274.00 | 2024 | Impella |
| Regeneron Healthcare Solutions, INC. | $270.75 | 2021-2025 | Libtayo |
| E.R. Squibb & Sons, L.L.C. | $230.90 | 2021-2024 | Opdivo, Krazati |
| Genzyme Corporation | $204.28 | 2021-2025 | |
| Astrazeneca Pharmaceuticals LP | $193.00 | 2022-2025 | Enhertu, Lynparza |
| Amgen INC. | $182.67 | 2021-2024 | Prolia |
| Merck Sharp & Dohme LLC | $151.79 | 2021-2025 | Keytruda, Lynparza, Keytruda Qlex |
| Incyte Corporation | $139.91 | 2022-2025 | Jakafi, Monjuvi, Niktimvo |
| Daiichi Sankyo INC. | $128.72 | 2024-2025 | Enhertu, Injectafer |
| Takeda Pharmaceuticals U.S.A., INC. | $110.56 | 2024-2025 | Iclusig, Ninlaro |
Show all 54 companies
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Brittani Reed listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.